





**Supplementary Table 2. Searching candidate causal SNPs tagged by rs73366469 in the 1000 Genomes Project**

1000 Genomes Project SNP	ImmunoChip SNP	Position on Chr7 (hg38)	Pairwise LD ( $r^2$ ) with rs73366469 in the 1000 Genomes Project subjects		
			Asian (n=286)	European (n=379)	African (n=246)
rs146236144	No	74580363	0.11	0.00	0.00
rs17145600	No	74580404	0.11	0.00	0.04
rs2267813	No	74582204	0.15	0.05	0.03
rs80346167	No	74586373	0.25	0.27	0.06
rs11981999	No	74587754	0.13	0.18	0.10
rs2005769	No	74590626	0.13	0.05	0.01
rs150108204	No	74594341	0.21	0.13	0.05
rs2019004	No	74595414	0.21	0.21	0.07
rs116657731	No	74597409	0.27	0.29	0.05
rs112806573	No	74598547	0.21	0.34	0.07
rs4717901	No	74602653	0.31	0.06	0.05
<b>rs12667901</b>	No	74607994	<b>0.73</b>	<b>0.40</b>	<b>0.31</b>
<b>rs73366456</b>	No	74608425	<b>0.74</b>	<b>0.40</b>	<b>0.39</b>
rs113066392	No	74611832	0.72	0.63	0.58
rs112502846	No	74611938	0.73	0.71	0.79
rs7800325	No	74618332	0.97	1.00	0.88
rs73366469	Yes	74619286	--	--	--
rs114860935	No	74620209	0.20	0.21	0.14
rs72038845	No	74622249	0.22	0.72	0.42
rs138731063	No	74622806	0.20	0.21	0.14
rs111273641	No	74624371	0.20	0.21	0.11
rs112504285	No	74625217	0.20	0.21	0.12
rs111527316	No	74631507	0.19	0.21	0.10
rs143176121	No	74694107	0.12	0.00	0.00
<b>rs117026326</b>	No	74711703	<b>0.53</b>	<b>0.17</b>	<b>0.00</b>

We hypothesized that Chinese, European Americans and African Americans might share the same causal variant tagged by rs73366469 which should be an untyped functional SNP in strong, modest and weak LD with rs73366469 in Chinese, European Americans and African Americans, respectively. By searching the 1000 Genomes Project phase 1 data set, we found 24 SNPs in LD with rs73366469 in Asians at the level of  $r^2 \geq 0.1$  (as shown in the table). None of the 24 SNPs were on the ImmunoChip. Of these SNPs, rs12667901, rs73366456 and rs117026326 (highlighted in bold and red) were in strong LD with rs73366469 in Asians (defined as  $r^2 > 0.5$ ) but not in Europeans and Africans. We hypothesized these three SNPs as candidate causal variants. To confirm this, rs12667901 and rs117026326 were genotyped using TaqMan assays and assessed for association with SLE. Because rs73366456 was in strong LD with rs12667901 in all three ancestral groups, it was not genotyped.

**Supplementary Table 3. Association of p.Arg90His with SLE in Asians**

Data set	Chinese-1		All subjects													
			MAF %		P after conditioning on									P <sub>HWE</sub>		
			Position on Chr7 (hg38)	Allele	SLE (n=436)	Control (n=586)	P	OR	95%CI	rs12667901	rs73366469	rs117026326	p.Arg90His	p.Ser99Gly	log <sub>10</sub> BF	PP
rs12667901	74607994	T/G	28.2	12.4	1.3E-15	2.90	2.23-3.76	--	2.0E-03	0.50	0.63	1.4E-06	10.9	0.00	0.72	0.01
rs73366469	74619286	C/T	29.7	13.9	1.7E-14	2.66	2.07-3.42	0.86	--	0.54	0.57	1.7E-06	10.0	0.00	0.91	0.02
rs117026326	74711703	T/C	28.1	11.4	1.8E-17	3.18	2.44-4.16	1.9E-03	7.8E-05	--	0.27	1.1E-07	12.6	0.00	0.55	0.01
p.Arg90His	74779296	A/G	38.1	15.6	2.6E-23	3.35	2.64-4.26	1.7E-10	6.0E-12	2.0E-08	--	2.5E-13	18.7	1.00	3.1E-03	0.64
p.Ser99Gly	74779322	G/A	43.2	26.8	1.6E-13	2.22	1.80-2.74	1.1E-03	5.2E-05	0.022	0.70	--	9.6	0.00	0.63	0.83

We measured the ΔGT/GTGT ratio for subjects from different ancestry groups and found the normal ratio of 4:2 in >98% Asian subjects ( Fig. 3c). Because the impact of mixture of 5:1, 3:3 and 2:4 ratios on association analyses of p.Arg90His in the Asian data sets was negligible (please see the Korean data set as shown below), subjects in the Korean-RA, Chinese-2 and Chinese-SS data sets and some subjects in the Chinese-1 data set were not assessed for the ΔGT/GTGT ratio. In the Chinese-1 data set, 313 cases and 102 controls were measured for the ΔGT/GTGT ratio, of which those with the ratio of 5:1 (2 cases) or 3:3 (3 cases and 3 controls) were excluded for association analyses. Bayes factor (shown as log<sub>10</sub>BF) was calculated based on the additive model, and posterior probability (shown as PP) was computed for each SNP.

Data set	Chinese-2		All subjects													
			MAF %		P after conditioning on									P <sub>HWE</sub>		
			Position on Chr7 (hg38)	Allele	SLE (n=746)	Control (n=1034)	P	OR	95%CI	rs12667901	rs73366469	rs117026326	p.Arg90His	p.Ser99Gly	log <sub>10</sub> BF	PP
rs12667901	74607994	T/G	27.6	13.0	3.9E-21	2.52	2.08-3.05	--	0.11	0.29	0.12	1.1E-08	16.9	0.00	1.00	0.10
rs73366469	74619286	C/T	30.0	15.2	6.5E-22	2.48	2.06-2.99	4.0E-03	--	0.33	0.046	4.3E-11	17.7	0.00	0.49	0.18
rs117026326	74711703	T/C	27.1	11.9	2.3E-24	2.82	2.31-3.44	6.0E-05	2.9E-05	--	0.093	9.0E-11	19.7	0.00	0.17	0.37
p.Arg90His	74779296	A/G	41.6	16.7	1.5E-41	3.27	2.75-3.88	7.7E-27	1.9E-26	2.9E-23	--	1.5E-25	39.2	1.00	3.9E-04	1.00
p.Ser99Gly	74779322	G/A	46.5	28.2	1.6E-22	2.13	1.83-2.48	9.4E-10	2.4E-11	3.7E-08	0.21	--	18.9	0.00	0.42	0.40

Subjects in the Chinese-2 dataset were not measured for the ΔGT/GTGT ratio. Association analyses were carried out in all subjects.

Chinese-1&2 combined		All subjects				
SNP		P <sub>meta</sub>	OR			
rs12667901		5.5E-35	2.65			log <sub>10</sub> BF PP
rs73366469		9.2E-35	2.55			32.9 0.00
rs117026326		4.4E-40	2.94			32.0 0.00
p.Arg90His		4.2E-63	3.30			37.2 0.00
p.Ser99Gly		2.1E-34	2.16			63.7 1.00
						30.6 0.00

Data set	Korean	Subjects with the ΔGT/GTGT ratio of 4:2												All subjects										
		MAF %		P after conditioning on									P <sub>HWE</sub>		MAF %		P after conditioning on							
		Position on Chr7 (hg38)	Allele	SLE (n=611)	Control (n=685)	P	OR	95%CI	--	--	rs117026326	p.Arg90His	p.Ser99Gly	log <sub>10</sub> BF	PP	SLE	Control	SLE (n=614)	Control (n=692)	P	OR	95%CI	rs117026326	p.Arg90His
rs117026326	74711703	T/C	30.0	11.4	3.3E-27	3.25	2.63-4.03	--	--	--	0.18	1.3E-10	23.1	0.0	1.00	0.06	29.9	11.4	3.0E-27	3.24	2.62-4.01	--	0.17	1.2E-10
p.Arg90His	74779296	A/G	46.6	18.1	2.6E-43	3.82	3.16-4.62	--	--	2.2E-22	--	2.3E-25	41.7	1.0	0.52	0.37	46.6	18.1	2.2E-43	3.80	3.14-4.59	1.9E-22	--	2.0E-25
p.Ser99Gly	74779322	G/A	52.4	30.5	3.2E-26	2.47	2.09-2.92	--	--	3.5E-08	0.052	--	22.7	0.0	0.57	0.59	52.4	30.6	2.8E-26	2.46	2.08-2.90	3.0E-08	0.043	--

All Korean subjects were measured for the ΔGT/GTGT ratio.

Association analyses were carried out either in subjects with the normal ΔGT/GTGT ratio of 4:2 (carrying 2 copies each of *NCF1*, *NCF1B* and *NCF1C*) or in all subjects.

**Supplementary Table 4. Association of p.Arg90His with SLE in European Americans**

Data set EurAm-1		All subjects										Subjects with the ΔGT/GTGT ratio of 4:2										$P_{HWE}$			
		MAF %		$P$ after conditioning on						MAF %		$P$ after conditioning on													
SNP	Allele	SLE (n=716)	Control (n=578)	$P$	OR	95%CI	rs12667901	rs73366469	rs117026326	p.Arg90His	p.Ser99Gly	SLE (n=612)	Control (n=485)	$P$	OR	95%CI	rs12667901	rs73366469	rs117026326	p.Arg90His	p.Ser99Gly	log <sub>10</sub> BF	PP	SLE	Control
rs12667901	T/G	5.4	3.6	0.028	1.56	1.05-2.32	--	0.37	0.57	0.34	0.12	4.9	3.4	0.057	1.55	0.99-2.44	--	0.34	0.78	0.79	0.021	0.2	0.04	0.39	1.00
rs73366469	C/T	11.2	8.3	0.010	1.43	1.09-1.87	0.21	--	0.13	0.22	0.10	10.8	8.5	0.036	1.37	1.02-1.84	0.36	--	0.29	0.64	0.12	0.4	0.05	1.00	0.37
rs117026326	T/C	2.4	0.87	7.2E-03	2.69	1.31-5.55	0.045	0.041	--	0.39	0.036	2.4	0.72	6.4E-03	3.25	1.39-7.56	0.022	0.018	--	0.59	0.019	0.4	0.05	1.00	1.00
p.Arg90His	A/G	8.2	4.1	2.1E-05	2.20	1.53-3.17	2.3E-04	3.6E-04	8.0E-04	--	3.4E-04	5.5	2.1	9.5E-05	2.83	1.68-4.77	8.0E-04	9.5E-04	2.9E-03	--	1.9E-03	1.4	0.61	1.00	1.00
p.Ser99Gly	G/A	17.7	12.5	1.2E-03	1.46	1.16-1.84	6.6E-03	0.014	0.010	0.027	--	17.8	13.0	3.9E-03	1.44	1.12-1.84	1.9E-03	0.016	0.025	0.12	--	1.1	0.25	0.41	0.84

All subjects in the EurAm-1 data set were measured for the ΔGT/GTGT ratio. Association analyses were carried out either in all subjects or in those with the normal ΔGT/GTGT ratio of 4:2.

Data set EurAm-2		All subjects										Subjects with the ΔGT/GTGT ratio of 4:2										$P_{HWE}$			
		MAF %		$P$ after conditioning on						MAF %		$P$ after conditioning on													
SNP	Allele	SLE (n=875)	Control (n=540)	$P$	OR	95%CI	rs12667901	rs73366469	rs117026326	p.Arg90His	p.Ser99Gly	SLE (n=736)	Control (n=446)	$P$	OR	95%CI	rs12667901	rs73366469	rs117026326	p.Arg90His	p.Ser99Gly	log <sub>10</sub> BF	PP	SLE	Control
rs12667901	T/G	5.9	4.2	0.040	1.46	1.02-2.11	--	0.46	0.62	0.48	0.55	5.4	3.7	0.035	1.59	1.03-2.45	--	0.50	0.66	0.50	0.52	0.3	0.03	0.26	0.46
rs73366469	C/T	12.0	9.0	0.019	1.37	1.05-1.79	0.25	--	0.20	0.22	0.25	11.9	8.5	0.012	1.46	1.09-1.97	0.15	--	0.16	0.25	0.14	0.7	0.06	1.00	1.00
rs117026326	T/C	2.4	0.74	5.7E-03	3.00	1.38-6.54	0.023	0.020	--	0.16	0.039	2.4	0.67	6.1E-03	3.51	1.43-8.59	0.026	0.023	--	0.29	0.032	0.4	0.03	0.36	1.00
p.Arg90His	A/G	8.3	4.2	3.3E-04	1.92	1.35-2.74	3.7E-03	3.3E-03	0.010	--	0.016	6.0	2.4	5.0E-04	2.42	1.47-3.98	4.2E-03	5.1E-03	0.017	--	0.023	1.3	0.23	0.04	1.00
p.Ser99Gly	G/A	18.2	13.0	3.8E-04	1.50	1.20-1.87	6.8E-03	6.0E-03	4.8E-03	0.026	--	18.6	13.1	5.5E-04	1.53	1.20-1.95	0.011	6.9E-03	6.6E-03	0.057	--	1.7	0.65	0.18	0.21

All subjects in the EurAm-2 data set were measured for the ΔGT/GTGT ratio. Association analyses were carried out either in all subjects or in those with the normal ΔGT/GTGT ratio of 4:2.

EurAm-1&2 combined		All subjects		Subjects with the ΔGT/GTGT ratio of 4:2			
SNP		$P_{meta}$	OR	$P_{meta}$	OR	log <sub>10</sub> BF	PP
rs12667901		2.7E-03	1.51	4.5E-03	1.57	0.9	0.00
rs73366469		5.0E-04	1.40	1.1E-03	1.42	1.6	0.00
rs117026326		1.2E-04	2.83	1.1E-04	3.37	1.4	0.00
p.Arg90His		3.0E-08	2.05	1.9E-07	2.61	4.1	0.83
p.Ser99Gly		1.5E-06	1.48	7.3E-06	1.49	3.4	0.17

**Supplementary Table 5. Association of p.Arg90His with SLE in African Americans**

<b>Data set AfrAm</b>			<b>All subjects</b>					<b>Subjects with the <math>\Delta</math>GT/GTGT ratio of 4:2</b>								
SNP	Position on Chr7 (hg38)	Allele	MAF %		<i>P</i>	OR	95%CI	MAF %		<i>P</i>	OR	95%CI	$\log_{10}$ BF	PP	<i>P</i> <sub>HWE</sub>	
			SLE (n=532)	Control (n=367)				SLE (n=474)	Control (n=315)						SLE	Control
rs73366469	74619286	C/T	17.7	19.6	0.32	0.88	0.69-1.13	18.5	19.5	0.66	0.94	0.73-1.23	-0.2	0.00	0.44	0.86
rs117026326 <sup>a</sup>	74711703	T/C	0.39	0.0	1.00	--	--	0.43	0.0	1.00	--	--	--	--	1.00	1.00
p.Arg90His	74779296	A/G	16.8	10.1	7.0E-05	1.80	1.35-2.40	15.7	8.3	2.9E-05	2.02	1.45-2.81	2.4	1.00	0.30	0.15
p.Ser99Gly	74779322	G/A	40.0	39.7	0.88	1.02	0.83-1.24	40.1	39.4	0.78	1.03	0.83-1.27	-0.3	0.00	0.45	0.41
Intronic-1 <sup>a</sup>	74780073	C/G	0.39	0.0	1.00	--	--	0.43	0.0	1.00	--	--	--	--	1.00	1.00
Intronic-2 <sup>a</sup>	74781840	A/C	0.39	0.0	1.00	--	--	0.43	0.0	1.00	--	--	--	--	1.00	1.00

All subjects in the AfrAm data set were measured for the  $\Delta$ GT/GTGT ratio.

Association analyses were carried out either in all subjects or in those with the normal  $\Delta$ GT/GTGT ratio of 4:2.

<sup>a</sup>rs117026326, intronic-1 and intronic-2 were genotyped in a subset of African-American subjects (382 cases and 227 controls).



**Supplementary Table 7. Association of p.Arg90His with primary Sjögren's syndrome in European Americans and Chinese**

Data set		Subjects with the $\Delta$ GT/GTGT ratio of 4:2														All subjects												
EurAm-SS		MAF %							P after conditioning on							P <sub>HWE</sub>			MAF %							P after conditioning on		
SNP	Position on Chr7 (hg38)	Allele	SS (n=302)	Control (n=931)	P	OR	95%CI	rs117026326	p.Arg90His	p.Ser99Gly	log <sub>10</sub> BF	PP	SS	Control	SS (n=373)	Control (n=1118)	P	OR	95%CI	rs117026326	p.Arg90His	p.Ser99Gly						
rs117026326	74711703	T/C	2.0	0.70	7.3E-03	3.12	1.36-7.17	--	0.36	0.017	0.2	0.21	1.00	1.00	1.9	0.81	0.018	2.43	1.16-5.09	--	0.28	0.042						
p.Arg90His	74779296	A/G	4.8	2.2	9.7E-04	2.35	1.42-3.91	0.036	--	4.0E-03	0.7	0.66	0.51	1.00	7.0	4.1	2.8E-03	1.75	1.21-2.53	0.038	--	0.016						
p.Ser99Gly	74779322	G/A	15.4	13.1	0.20	1.19	0.91-1.55	0.54	0.927	--	0.0	0.13	0.51	0.56	15.0	12.8	0.19	1.18	0.92-1.50	0.50	0.50	--						

All subjects in the EurAm-SS data set were measured for the  $\Delta$ GT/GTGT ratio. Association analyses were carried out either in all subjects or in those with the normal  $\Delta$ GT/GTGT ratio of 4:2.

Data set		All subjects																
Chinese-SS		MAF %							P after conditioning on							P <sub>HWE</sub>		
SNP	Position on Chr7 (hg38)	Allele	SS (n=449)	Control (n=469)	P	OR	95%CI	rs117026326	p.Arg90His	p.Ser99Gly	log <sub>10</sub> BF	PP	SS	Control				
rs117026326	74711703	T/C	26.2	14.7	4.6E-09	2.03	1.60-2.57	--	0.29	1.9E-03	5.6	0.00	0.71	0.71				
p.Arg90His	74779296	A/G	37.8	18.3	7.2E-17	2.45	1.98-3.02	4.3E-10	--	7.3E-13	13.0	1.00	1.2E-03	0.35				
p.Ser99Gly	74779322	G/A	41.5	29.1	9.7E-08	1.68	1.39-2.04	0.064	0.017	--	4.9	0.00	0.02	0.74				

Subjects in the Chinese-SS data set were not measured for the  $\Delta$ GT/GTGT ratio. Association analyses were carried out in all subjects.



**Supplementary Table 8. Independent association of p.Arg90His with seropositive rheumatoid arthritis in Koreans**

Data set	Korean-RA		MAF %		<i>P</i> afte conditioning on					<i>P</i> <sub>HWE</sub>			
	SNP	Position on Chr7 (hg38)	Allele	RA (n=863)	Control (n=685)	<i>P</i>	OR	95%CI	p.Arg90His	p.Ser99Gly	log <sub>10</sub> BF	PP	RA
p.Arg90His	74779296	A/G	26.6	18.1	2.5E-08	1.65	1.38-1.97	--	1.1E-05	5.5	1.00	0.30	0.45
p.Ser99Gly	74779322	G/A	35.2	30.5	2.0E-03	1.27	1.09-1.49	0.94	--	1.4	0.00	0.55	0.93

Korean patients with rheumatoid arthritis were not measured for the ΔGT/GTGT ratio.

Korean controls were measured for the ΔGT/GTGT ratio, and only those with the 4:2 ratio were included in associaton analyses.

**Supplementary Table 9. Association of copy number variation of *NCF1* with SLE and SS**

Disease	Ancestry	Subject		5:1 ratio					3:3 and 2:4 ratio					4:2 ratio (reference)	
		Case	Control	N <sup>a</sup> (frequency%)		P	OR	95% CI	N <sup>a</sup> (frequency%)		P	OR	95% CI	N <sup>a</sup> (frequency%)	
				Case	Control				Case	Control				Case	Control
SLE	Korean	829	782	3 (0.4)	0 (0.0)	0.032	-	-	0 (0.0)	7 (0.9)	3.7E-05	--	--	826 (99.6)	775 (99.1)
SLE	Chinese	511	573	3 (0.6)	0 (0.0)	0.011	-	-	3 (0.6)	12 (2.1)	2.8E-03	0.28	0.11-0.68	505 (98.8)	561 (97.9)
SLE	EurAm	1593	1118	17 (1.1)	3 (0.3)	5.9E-04	3.91	1.64-9.33	227 (14.2)	184 (16.5)	0.038	0.85	0.73-0.99	1349 (84.7)	931 (83.3)
SLE	AfrAm	716	406	4 (0.6)	1 (0.2)	0.509	2.19	0.46-10.4	73 (10.2)	55 (13.5)	0.018	0.73	0.56-0.95	639 (89.2)	350 (86.2)
SS	EurAm	382	1118	3 (0.8)	3 (0.3)	0.085	3.02	0.97-9.41	71 (18.6)	184 (16.5)	0.163	1.17	0.94-1.45	308 (80.6)	931 (83.3)

<sup>a</sup>number

**Supplementary Table 10. *NCF1*-specific PCR and sequencing primers**

PCR product	PCR primer	Sequencing primer
P1 (3375bp)	P1-L (forward): 5'-GCAAAGCCCTTTCTGTACCC P1-R (reverse): 5'-TCACCAGGAACATGTACACCTG	P1-1: 5'-GCAAAGCCCTTTCTGTACCC P1-2: 5'-AGGCCAGGGAGGAACTACAT P1-3: 5'-CGTGAGCTACCGTGCCTAGT P1-4: 5'-ATCCACTGCCCTGGATACAC P1-5: 5'-CGGATTCTGGATCGGTCTTA P1-6: 5'-TCACCAGGAACATGTACACCTG P1-7: 5'-GTTTGTGCCCTTTCTGCAAT
P2 (6466bp)	P2-L (forward): 5'-GCTTTCCCCCAGGTGTACA P2-R (reverse): 5'-CCCAGACTCCAAAGCAGTCA	P2-1: 5'-AAAGCGACAAGAATGGTTCC P2-2: 5'-TAACGAAAATGGCCTCCTTG P2-3: 5'-CCTTGTGGTTCTCGTCCCTA P2-4: 5'-AGCAAAGGATTTGCTGGTG P2-5: 5'-CTGTCAGGGGGTCATTGG P2-6: 5'-TGTCTGGGGTCTCCTGTACC P2-7: 5'-CCTGAACACTCTGGGTCTCC P2-8: 5'-TGGGAAGTTCTTCTGCAGGT P2-9: 5'-TTTCTGACCAGCCCTTCATC P2-10: 5'-AGGGCCCCTACTACTGACCT P2-11: 5'-TTGTGGCTGTGGGTTCT P2-12: 5'-CCCAGACTCCAAAGCAGTCA
P3 (6298bp)	P3-L (forward): 5'-AAGGCTCAGGCAGCCTTG P3-R (reverse): 5'-CAGACCTCGGCTCTTGCAACTT	P3-1: 5'-GTGTCCTCACCATCCCTGAT P3-2: 5'-TTACAAGCATGCACCACCAT P3-3: 5'-TCTACCTGGCACTGGGAAT P3-4: 5'-ACCCAGATCCCTAAACACC P3-5: 5'-AGGCGCAGAGAGGAGAAGAT P3-6: 5'-TGGGGTCAAGTGATCCTTTC P3-7: 5'-TCATGCCTGTAATCCCAACA P3-8: 5'-CTCCAGCTTGGGAGTCAGAG P3-9: 5'-TTTCTGGTTCTGGGGAACAC P3-10: 5'-TCCTGTCTCAGCTTCCCAAG P3-11: 5'-ATGGCCTAGACAGAGCGAAC P3-12: 5'-AGAGAGCCCTGAAACCCTCT P3-13: 5'-CCCAGCAGAACTCACAACCT
P2* (2208bp)	P2-L* (forward): 5'-GCTTTCCCCCAGGTGTAC P2-R* (reverse): 5'-CCTTCCCTCTCCACCT	

**Supplementary Table 11. TaqMan assays for SNP genotyping and the  $\Delta$ GT/GTGT ratio**

Target	Forward Primer Sequence	Reverse Primer Sequence	Reporter 1 Sequence	Reporter 2 Sequence
rs12667901	TGGTGACGGATGCCTGTAATC	ACCTTCTGGTTTCAAGCGATTCTC	CTGCCTCAGCCTCCCGA	CTGCCTCAGACTCCCGA
rs73366469	CGTGTGCCTGAGCAATTGAG	ACAGCCTGGCCCTCTCT	CTTCCTCCTGCAGGCC	TCCTCCCGCAGGCC
rs117026326	GGTTAGTTTGCATTTTCTATAAAAGTCTTATGAATGAAATA	GCTGTGGATGAATTTCAAACAATCATT	CTCCCCGGCCCATG	CTCCCCAGCCCATG
p.Arg90His	CAGCTCCCAAGTGGTTTGAC	GGTGGGCAGGCTCATGA	CCTGGCGGTTCTC	CCTGGTGGTTCTC
p.Ser99Gly	CGGGCCGCCGAGAA	TGGTGGGCAGGCTCATG	AGTACTGCGGCACGCT	AGTACTGCAGCACGCT
Intronic-1	AGCACTTATTGACGCTTGAAGGT	GCCTCCCGGGCTGATG	CTGCCCTTCCTTGGGC	TGCCCTTCGTTGGGC
Intronic-2	CCTCCCAAAGTGCTGAGATTATAGA	CAACAGGCCTCGTGCCTTA	CCGGCTTTTTCTTCTTCTTA	CGGCTTTTTCTTATTCTTA
GTGT	CCCCGACTCTGGCTTTCC	CCGACAGGTCCTGCCATT	CCCAGGTGTACATGTT	
$\Delta$ GT	CCCCGACTCTGGCTTTCC	CCGACAGGTCCTGCCATT	CCCAGGTACATGTTCT	